Aethlon Medical grants Larosa 42,000 stock units

Aethlon Medical Inc. Chief Medical Officer Steven P. Larosa acquired 42,000 restricted stock units (RSUs) on October 8, 2026, under the company's 2020 Equity Incentive Plan, as amended.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aethlon Medical Inc. Chief Medical Officer Steven P. Larosa acquired 42,000 restricted stock units (RSUs) on October 8, 2026, under the company's 2020 Equity Incentive Plan, as amended. Each RSU is a contingent right to receive one common share upon settlement. The units vest over the one-year period following October 8, 2026, subject to continued service through applicable vesting dates, and will become fully vested upon closing of Aethlon Medical's proposed merger with North Immunology, Inc. Larosa's reported direct holdings following the grant were 42,057 shares.

Insider Trade Summary

Grant/Award: 42,000 shares

Grant/Award 1 txn

Insider LAROSA STEVEN P

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	42,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 42,057 shares (Direct)

Footnotes (1)

F1. Represents a grant of 42,000 restricted stock units ("RSUs") pursuant to the Issuer's 2020 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest over the one-year period following October 8, 2026, subject to the Reporting Person's continued service through the applicable vesting dates. Notwithstanding the foregoing, the RSUs will become fully vested upon the closing of the Issuer's proposed merger with North Immunology, Inc.

Key Figures

Restricted stock units granted: 42,000 RSUs Shares per RSU: 1 common share Reported direct holdings after grant: 42,057 shares +1 more

4 metrics

Restricted stock units granted 42,000 RSUs Granted October 8, 2026

Shares per RSU 1 common share Contingent right upon settlement

Reported direct holdings after grant 42,057 shares Following the October 8, 2026 transaction

Vesting period One year Following October 8, 2026, subject to continued service

Key Terms

restricted stock units, contingent right, vesting

3 terms

restricted stock units financial

"grant of 42,000 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"contingent right to receive one share"

vesting financial

"vest over the one-year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs did AEMD's chief medical officer receive?

Aethlon Medical Inc. Chief Medical Officer Steven P. Larosa received a grant of 42,000 RSUs on October 8, 2026. Each RSU represents a contingent right to receive one common share upon settlement.

When do AEMD's 42,000 RSUs vest?

The RSUs vest over the one-year period following October 8, 2026, subject to Larosa's continued service through the applicable vesting dates. They will become fully vested upon closing of Aethlon Medical's proposed merger with North Immunology, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/15/2026 - 04:08 PM EDT Accepted by SEC EDGAR 10/15/2026 - 04:08 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAROSA STEVEN P

(Last)

(First)

(Middle)

11555 SORRENTO VALLEY ROAD, SUITE 203

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/08/2026		A		42,000⁽¹⁾	A	$0.00	42,057	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of 42,000 restricted stock units ("RSUs") pursuant to the Issuer's 2020 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest over the one-year period following October 8, 2026, subject to the Reporting Person's continued service through the applicable vesting dates. Notwithstanding the foregoing, the RSUs will become fully vested upon the closing of the Issuer's proposed merger with North Immunology, Inc.

	/s/ Steven P. LaRosa By: James B. Frakes, Attorney in Fact	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR